From lab to scalable siRNA-loaded Lipid@PLGA hybrid nanoparticles production via double-chip configuration

Teresa Silvestri – Assistant Professor, Department of Pharmacy, University of Naples Federico II; Susy Brusco – PhD, Department of Pharmacy, University of Naples Federico II; Erika Esposito – PhD Student, Department of Pharmacy, University of Naples Federico II; Chiara Indolfi – PhD student, Department of Pharmacy, University of Naples Federico II; Thomas Lee Moore – Tenure-track Assistant Professor, Department of Pharmacy, University of Naples Federico II; Emma Mitidieri – Associate Professor, Department of Pharmacy, University of Naples Federico II; Raffaella Sorrentino – Full Professor, Department of Pharmacy, University of Naples Federico II; Fabiana Quaglia – Full Professor, Department of Pharmacy, University of Naples Federico II; Paola Brocca – Associate Professor, Department of Medical Biotechnology and Translational Medicine, University of Milano; Ivana d'Angelo – Associate Professor, Di.S.T.A.Bi.F, University of Campania Luigi Vanvitelli; Roberta d'Emmanuele di Villa Bianca – Associate Professor, Department of Pharmacy, University of Naples Federico II; Gabriella Costabile – Assistant Professor, Department of Pharmacy, University of Naples Federico II; Francesca Ungaro – Full Professor, Department of Pharmacy, University of Naples Federico II

Introduction:

The growing interest in developing therapeutic RNAs has consequently boosted research efforts toward the transition from lab-scale processes to large-scale manufacturing, with the aim of ensuring batch-to-batch consistency (1). In the specific context of pulmonary delivery of siRNA, our research group has designed hybrid core–shell nanoplatforms consisting of a poly(lactide-co-glycolide) (PLGA) core surrounded by a lipid shell (Lipid@PLGA hNPs), which have shown great potential for the local treatment of severe lung diseases (2,3).